Kailera Therapeutics, Inc. (KLRA) Revenue, Earnings & Financial Statements
$12.20NASDAQ: KLRAMarket Cap $1.58B
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
Kailera Therapeutics, Inc. most recently reported annual revenue of $0, a net loss of $149.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Income Statement — 1 Years (USD millions)
Metric
2025
Revenue
$0
Operating Expenses
$158.0M
Operating Profit
−$158.0M
Other Income
$9.0M
Interest
$0
Depreciation
$0
Profit Before Tax
−$149.0M
Tax rate (%)
0.0%
Net Profit
−$149.0M
EPS
−$1.26
Quarterly Results — Last 4 Quarters (USD millions)
Metric
Dec '25
Mar '26
Jun '26
Sep '26
Revenue
$0
$0
$0
$0
Operating Expenses
$67.0M
$85.0M
$121.0M
$106.0M
Operating Profit
−$67.0M
−$85.0M
−$121.0M
−$106.0M
Interest
$0
$0
$0
$0
Profit Before Tax
−$62.0M
−$79.0M
−$111.0M
−$96.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
Net Profit
−$62.0M
−$79.0M
−$111.0M
−$96.0M
EPS
−$0.53
−$0.67
−$1.09
−$0.74
Balance Sheet — 1 Years (USD millions)
Metric
2025
Total Assets
$692.0M
Current Assets
$558.0M
Cash
$160.0M
Inventory
$0
Receivables
$3.0M
Fixed Assets
$12.0M
Capital Work in Progress
$0
Investments
$492.0M
Other Assets
$0
Total Liabilities
$1.0B
Current Liabilities
$46.0M
Borrowings
$11.0M
Other Liabilities
$1.0B
Equity
$0
Reserves
−$356.0M
Cash Flow Statement — 1 Years (USD millions)
Metric
2025
Operating Cash Flow
−$120.0M
Investing Cash Flow
−$495.0M
Financing Cash Flow
−$499.0M
Net Cash Flow
−$14.0M
Free Cash Flow
−$122.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
0.04
EV / EBITDA
-4.03
FCF Yield
-20.66%
Quick Ratio
21.84
Interest Coverage
—
Return 1Y
—
Return 3Y
—
Return 5Y
—
Kailera Therapeutics, Inc. (KLRA) financials — frequently asked questions
What is Kailera Therapeutics, Inc.'s annual revenue?
Kailera Therapeutics, Inc. (KLRA) reported annual revenue of $0 in its most recent fiscal year.
What is Kailera Therapeutics, Inc.'s net profit?
Kailera Therapeutics, Inc. (KLRA) reported a net loss of $149.0M in its most recent fiscal year.
What is KLRA EV/EBITDA?
Kailera Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -4.03. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Biotechnology stocks